R
Ronald F van Vollenhoven
Researcher at University of Amsterdam
Publications - 354
Citations - 32567
Ronald F van Vollenhoven is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 72, co-authored 309 publications receiving 26884 citations. Previous affiliations of Ronald F van Vollenhoven include Karolinska Institutet & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Edward C. Keystone,Robert Landewé,Ronald F van Vollenhoven,Bernard Combe,Vibeke Strand,Philip J. Mease,Laura Shaughnessy,B. VanLunen,Désirée van der Heijde +8 more
TL;DR: CZP+MTX treatment provided a favourable risk-benefit profile over 5 years in patients with active rheumatoid arthritis, and no new safety signals were identified.
Journal ArticleDOI
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
Michael Schiff,Tsutomu Takeuchi,Roy Fleischmann,Carol L. Gaich,Amy M. DeLozier,Douglas E Schlichting,Wen Ling Kuo,Ji Eon Won,Tara Carmack,Terence Rooney,Patrick Durez,Patrick Durez,S. Shaikh,Rodolfo Pardo Hidalgo,Ronald F van Vollenhoven,Cristiano A. F. Zerbini +15 more
TL;DR: In this study, baricitinib alone or in combination with MTX, when used as initial therapy, resulted in significant improvement compared to MTX in the majority of the pre-specified PRO measures.
Journal ArticleDOI
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
TL;DR: Clinical data suggest that the combination of etanercept plus MTX is clinically more efficacious than etanorcept alone, while other disease outcomes showed non-significant trends in the same direction.
Journal ArticleDOI
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
Merete Lund Hetland,Espen A Haavardsholm,Anna Rudin,Dan Nordström,M. T. Nurmohamed,Bjorn Gudbjornsson,Jon Lampa,Kim Hørslev-Petersen,Till Uhlig,Gerdur Gröndal,Mikkel Østergaard,Marte Schrumpf Heiberg,Jos W. R. Twisk,Kristina Lend,Simon Krabbe,Lise Hyldstrup,Joakim Lindqvist,Anna-Karin H. Ekwall,Kathrine Lederballe Grøn,Meliha C Kapetanovic,F. Faustini,Riitta Tuompo,Tove Lorenzen,Giovanni Cagnotto,Eva Baecklund,Oliver Hendricks,Daisy Vedder,T. Sokka-Isler,Tomas Husmark,Maud Kristine Aga Ljoså,Eli Brodin,Torkell Ellingsen,Annika Soderbergh,Milad Rizk,Åsa Reckner Olsson,Per Larsson,Line Uhrenholt,Søren Andreas Just,David John Stevens,Trine Bay Laurberg,Gunnstein Bakland,Inge C. Olsen,Ronald F van Vollenhoven,Ronald F van Vollenhoven +43 more
TL;DR: The results highlight the efficacy and safety of active conventional treatment based on methotrexate combined with corticosteroids and certification pegol and tocilizumab, but not to abatacept, and show no major differences among the four treatments.
Journal ArticleDOI
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
Andrea Rubbert-Roth,Anthony Sebba,Laura Brockwell,Ariella Kelman,Benjamin Porter-Brown,Jennifer Pulley,Pavel Napalkov,Ronald F van Vollenhoven +7 more
TL;DR: Malignancy rates remained stable with long-term tocilizumab treatment, and malignancy types and rates were consistent with those expected in patients with RA.